N. Vorokhobina

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

J. Rosenstock, R. Heine, S. Kahn, 2021, The Lancet.

Efficacy and safety of Subetta add-on therapy in type 1 diabetes mellitus: The results of a multicenter, double-blind, placebo-controlled, randomized clinical trial.

A. Mkrtumyan, M. Putilovskiy, E. Andrianova, 2018, Diabetes research and clinical practice.

[Fibroblast growth factor-21 as a marker of premature aging in young and middled-aged men with type 2 diabetes].

N. Vorokhobina, E. Zagarskikh, G. A. Proshchai, 2018, Urologiia.

Macrophage stimulating agent soluble yeast β‐1,3/1,6‐glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo‐controlled phase II study

R. Engstad, K. A. Balandina, A. Kuznetsova, 2013, Journal of diabetes investigation.

Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes

S. Jain, M. Escalante-Pulido, L. Ilag, 2010, Diabetes, obesity & metabolism.

Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.

R. Aronson, B. Ahrén, E. Souhami, 2014, Journal of diabetes and its complications.

Tirzepatide Once Weekly for the Treatment of Obesity.

L. Aronne, I. Lee, J. Ard, 2022, The New England journal of medicine.

Prognostic markers of recurrence in adrenocortical carcinoma patients after surgery

N. Kushlinskii, V. Bokhyan, N. Vorokhobina, 2023, HERALD of North-Western State Medical University named after I.I. Mechnikov.

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

I. Lee, J. Ard, J. Rosenstock, 2023, The Lancet.